Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Return on Sales (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Return on Sales data on record, last reported at 4.92% in Q4 2025.

  • For Q4 2025, Return on Sales fell 206.0% year-over-year to 4.92%; the TTM value through Dec 2025 reached 5.07%, down 248.0%, while the annual FY2025 figure was 5.07%, 248.0% down from the prior year.
  • Return on Sales reached 4.92% in Q4 2025 per OCUL's latest filing, down from 4.67% in the prior quarter.
  • Across five years, Return on Sales topped out at 1.42% in Q3 2023 and bottomed at 5.9% in Q1 2025.
  • Average Return on Sales over 5 years is 2.59%, with a median of 1.9% recorded in 2022.
  • Peak YoY movement for Return on Sales: soared 1060bps in 2021, then tumbled -375bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 1.6% in 2021, then grew by 8bps to 1.48% in 2022, then decreased by -4bps to 1.54% in 2023, then tumbled by -87bps to 2.87% in 2024, then tumbled by -72bps to 4.92% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 4.92% in Q4 2025, 4.67% in Q3 2025, and 4.99% in Q2 2025.